Please try another search
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Name | Age | Since | Title |
---|---|---|---|
Steven C. Quay | 71 | 2009 | Chairman, CEO & President |
H. Lawrence Remmel | 71 | 2012 | Independent Director |
Stephen J. Galli | 76 | 2011 | Independent Director |
Richard I. Steinhart | 66 | 2014 | Independent Director |
Shu-Chih Chen | 61 | 2009 | Director |
Jonathan Frederick Finn | - | 2023 | Director |
Tessa Cigler | 50 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review